Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] APL is engaged in the business of marketing and distribution of finished pharma formulations. It does not have its own manufacturing unit, but does the business on third party contract. The company posted growth in its top and bottom lines for the reported period, however, sudden boost in bottom line for FY25 raise eyebrows and concern over its sustainability. Based on its recent financial data, the issue appears aggressively priced. Small paid-up equity capital post-IPO indicates longer gestation period for migration. Only well-informed/risk seekers/cash surplus investors may park moderate funds for long term Read detail review...
Aptus Pharma Ltd. peer comparison with similar listed entities. (As on March 31, 2025)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Aptus Pharma Limited | 5.32 | 5.32 | 13.93 | 44.50 | Restated | ||
| Zota Health Care Limited | 3.16 | 3.16 | 110.83 | 382.12 | 2.72 | 10.97 | Restated |
| Sunrest Lifescience Limited | 4.66 | 4.66 | 37.72 | 10.56 | 12.36 | 1.32 | Restated |
| Lincoln Pharmaceuticals Limited | 41.11 | 41.11 | 335.34 | 13.53 | 12.26 | 1.66 | Restated |
Notes:
Aptus Pharma IPO Reviews, analysis and views by popular members. Read Aptus Pharma Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Post Recommendation Manage Recommendations
Note:
RHP